Evaluation of the Vasoprotective Effects of Metformin versus Glibenclamide in Type 2 Diabetic Patients-Reference-Cited by-同舟云学术

Evaluation of the Vasoprotective Effects of Metformin versus Glibenclamide in Type 2 Diabetic Patients

Published:2021-12-28 Issue: Volume: Page:6409-6412
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

H. Fathi Zainab¹,Mohammad Jehan A.¹,H. Mohammed Marwah²

Affiliation:

1. Department of Pharmacognosy and Medicinal Plants, College of Pharmacy, University of Mosul, Mosul-Iraq.

2. Department of Clinical Laboratory Sciences, College of Pharmacy, University of Mosul, Mosul-Iraq.

Abstract

Adiponectin (APN) is an adipokine with anti-inflammatory and anti-atherogenic properties decreased in type 2 diabetes mellitus (T2DM) that may influence endothelial function by regulating serum nitric oxide (NO) levels. The current study aimed to investigate the effect of two oral hypoglycemic drugs, Metformin and Glibenclamide (GLC), on circulating APN and NO levels and to find a correlation between APN and NO levels in type 2 diabetic patients. Fifty males and females previously diagnosed with T2DM were conducted in this trial and classified into groups: Group A involved 18 untreated patients with T2DM, group B involved 16 patients receiving Metformin monotherapy (1000 mg/day) for up to 1 year and group C involved 16 patients receiving GLC (5 mg/day) for up to 1 year. Circulating APN and NO were measured. Compared to GLC, Metformin therapy showed a significant increase in APN and NO levels in type 2 diabetic patients. Our findings established that Metformin has a protective effect on endothelial function, including increased APN and NO bioavailability, beyond its glucose-lowering effect.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference41 articles.

1. Zheng Y., Ley S.H., Hu F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature reviews. Endocrinology. 2018;14(2):88.

2. Nanditha A., Ma R.C.W., Ramachandran A., Snehalatha C., Chan J.C.N., Chia K.S., et al. Diabetes in Asia and the Pacific: Implications for the Global Epidemic. Diabetes Care. 2016;39(3):472.

3. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H., and the W.H.O.M.S.G. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(2):S14.

4. Rojas L.B.A., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6.

5. Tokubuchi I., Tajiri Y., Iwata S., Hara K., Wada N., Hashinaga T., et al. Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats. PLoS One. 2017;12(2):e0171293.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ASSESSMENT OF OXIDATIVE STRESS AND ANTIOXIDANT STATUS IN TYPE 1 DIABETES MELLITUS;Military Medical Science Letters;2023-09-01

2. HYPERLIPIDEMIA CONNOTED VITIATION OF SERUM ADIPOKINES AND REDOX IMBALANCES;Military Medical Science Letters;2023-06-02

3. THERAPEUTIC USE OF METFORMIN IN THYROID CANCER;Military Medical Science Letters;2022-12-02